NextCure Accounts Payable from 2010 to 2024
| NXTC Stock | USD 1.45 0.02 1.36% |
Accounts Payable | First Reported 2018-12-31 | Previous Quarter 4.5 M | Current Value 5.1 M | Quarterly Volatility 1.1 M |
Check NextCure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NextCure's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 3.2 M or Interest Expense of 6.4 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 0.29. NextCure financial statements analysis is a perfect complement when working with NextCure Valuation or Volatility modules.
NextCure | Accounts Payable |
Latest NextCure's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of NextCure over the last few years. An accounting item on the balance sheet that represents NextCure obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NextCure are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. NextCure's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NextCure's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
NextCure Accounts Payable Regression Statistics
| Arithmetic Mean | 1,915,484 | |
| Geometric Mean | 1,698,255 | |
| Coefficient Of Variation | 55.10 | |
| Mean Deviation | 833,381 | |
| Median | 1,141,000 | |
| Standard Deviation | 1,055,441 | |
| Sample Variance | 1.1T | |
| Range | 3.1M | |
| R-Value | 0.74 | |
| Mean Square Error | 546B | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | 174,210 | |
| Total Sum of Squares | 15.6T |
NextCure Accounts Payable History
About NextCure Financial Statements
NextCure stakeholders use historical fundamental indicators, such as NextCure's Accounts Payable, to determine how well the company is positioned to perform in the future. Although NextCure investors may analyze each financial statement separately, they are all interrelated. For example, changes in NextCure's assets and liabilities are reflected in the revenues and expenses on NextCure's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NextCure. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 2.3 M | 2.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out the analysis of NextCure Correlation against competitors. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.